Presentation is loading. Please wait.

Presentation is loading. Please wait.

Patient disposition during open-label longterm exposure period.

Published bySuryadi Ade Halim Modified over 5 years ago

Similar presentations

Presentation on theme: "Patient disposition during open-label longterm exposure period."— Presentation transcript:

1 Patient disposition during open-label longterm exposure period.
Patient disposition during open-label longterm exposure period. AE: adverse event; Auto Ab+: autoantibody positive; DB: double-blind; DC: discontinuation; Dis prog: disease progression; Inv dec: investigator decision; Lack compl: lack of compliance; LTC: longterm continuation; LTFU: lost to followup; Pat req: patient request. From Wallace DJ, et al. Arthritis Care Res 2009;61:1168–78; and Merrill JT, et al. Arthritis Rheum 2012;64:3364–73. Ellen M. Ginzler et al. J Rheumatol 2014;41: ©2014 by The Journal of Rheumatology

Download ppt "Patient disposition during open-label longterm exposure period."

Similar presentations

Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI438011 Study  TAF (TFV prodrug) –Study 292-0102 –Study 299-0102  Doravirine.

Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI Study  TAF (TFV prodrug) –Study –Study  Doravirine.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
High Impact Rheumatology For Primary Care Physicians.

High Impact Rheumatology For Primary Care Physicians.
OBJECTIVES and METHODOLOGY

OBJECTIVES and METHODOLOGY
Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Naïve GT 1-6 POLARIS-2

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Naïve GT 1-6 POLARIS-2
Algorithm for diagnosis and initial therapy of systemic lupus erythematosus (SLE). For guidelines on management of lupus and lupus nephritis, see BH Hahn.

Algorithm for diagnosis and initial therapy of systemic lupus erythematosus (SLE). For guidelines on management of lupus and lupus nephritis, see BH Hahn.
William B. White, MD, Robert A. Hauser, MD, MBA, Gerald J

William B. White, MD, Robert A. Hauser, MD, MBA, Gerald J
Rates of Ambulatory Care Visits for Treating Adverse Drug Events (VADEs): Trend 1995–2001 Data: National Ambulatory Medical Care Survey and National Hospital.

Rates of Ambulatory Care Visits for Treating Adverse Drug Events (VADEs): Trend 1995–2001 Data: National Ambulatory Medical Care Survey and National Hospital.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Patient disposition for the double-blind study period.

Patient disposition for the double-blind study period.
Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 4 Antinuclear antibodies and disease activity in SLE
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.
MTX Lung vs. Rheumatoid Lung Disease

MTX Lung vs. Rheumatoid Lung Disease
Percentage of patients achieving minimal disease activity (MDA): A

Percentage of patients achieving minimal disease activity (MDA): A
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Similar presentations

Ads by Google